Clinical Trials

Several clinical trials evaluate interventions related to Morin across diverse conditions, including insomnia, schizophrenia, schizoaffective disorder, COVID-19, and mental health impairments. Designated with a non-applicable phase status, these trials are sponsored by academic and public health institutions, including Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Hospital Authority Hong Kong, and Helsinki University Central Hospital. Active recruitment statuses across these records encompass both recruiting and unknown status.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05231018 Unknown status
COVID-19|Mental Health Impairment|Telemedicine
Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico
 2020-10-28 Not Applicable
NCT04653155 Unknown status
Insomnia
Hospital Authority Hong Kong
 2020-06-01 Not Applicable
NCT04144231 Recruiting
Insomnia|Schizophrenia|Schizoaffective Disorder
Helsinki University Central Hospital|University of Helsinki|Finnish Institute for Health and Welfare|Finnish Institute of Occupational Health
 2019-12-19 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Morin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Morin binds to and inhibits DNA topoisomerase while modulating inflammatory enzymatic pathways, thereby blocking downstream biochemical cascades and reducing cellular oxidative stress and aberrant signal transduction. This biochemical attenuation delivers neuroprotective and anti-inflammatory effects that are clinically relevant to managing central nervous system and psychiatric conditions such as insomnia, schizophrenia, and mental health impairments associated with viral infections like COVID-19.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.